Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 90/100

Failure Rate

30.4%

7 terminated/withdrawn out of 23 trials

Success Rate

69.6%

-16.9% vs industry average

Late-Stage Pipeline

13%

3 trials in Phase 3/4

Results Transparency

31%

5 of 16 completed trials have results

Key Signals

5 with results7 terminated

Enrollment Performance

Analytics

Phase 1
18(78.3%)
Phase 3
3(13.0%)
Phase 2
2(8.7%)
23Total
Phase 1(18)
Phase 3(3)
Phase 2(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (23)

Showing 20 of 23 trials
NCT04964505Phase 1Terminated

Uproleselan, Azacitidine, and Venetoclax for the Treatment of Treatment Naive Acute Myeloid Leukemia

Role: collaborator

NCT02187003Phase 3Completed

Efficacy and Safety of Rivipansel (GMI-1070) in the Treatment of Vaso-Occlusive Crisis in Hospitalized Subjects With Sickle Cell Disease

Role: collaborator

NCT05569512Phase 1Terminated

Uproleselan With Pre-Transplant Conditioning in Hematopoietic Stem Cell Transplantation for AML

Role: collaborator

NCT03616470Phase 3Terminated

Study to Determine the Efficacy of Uproleselan (GMI-1271) in Combination With Chemotherapy to Treat Relapsed/Refractory Acute Myeloid Leukemia

Role: lead

NCT04682405Phase 2Completed

Uproleselan (GMI-1271) for GI Toxicity Prophylaxis During Melphalan-Conditioned Autologous Hematopoietic Cell Transplantation (Auto-HCT) for Multiple Myeloma (MM)

Role: collaborator

NCT05057221Phase 1Terminated

Safety, Tolerability and Efficacy of Uproleselan (GMI-1271) in Patients With COVID-19 Pneumonia

Role: collaborator

NCT04197999Phase 1Terminated

A Study to Determine Safety and Tolerability of GMI-1359 in Subjects With HR+ Metastatic Breast Cancer

Role: lead

NCT02433158Phase 3Terminated

Safety of Rivipansel (GMI-1070) in the Treatment of One or More Vaso-Occlusive Crises in Hospitalized Subjects With Sickle Cell Disease

Role: lead

NCT02871570Phase 1Completed

A Study to Evaluate the Effect of IV Doses of Rivipansel in Subjects With Moderate Hepatic Impairment and in Healthy Subjects With Normal Hepatic Function

Role: lead

NCT02813798Phase 1Completed

A Study to Evaluate the Effect of IV Doses of Rivipansel on Subjects With Renal Impairment and in Healthy Subjects

Role: lead

NCT02998099Phase 1Completed

A Study to Evaluate the Effect of Age on the Pharmacokinetics, Safety and Tolerability of IV Rivipansel.

Role: lead

NCT02217917Phase 1Completed

Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Subcutaneous Rivipansel With rHuPH20 in Healthy Subjects

Role: lead

NCT01941511Phase 1Completed

A Study to Evaluate the Effect of IV Doses of GMI-1070 on Qtc Intervals in Healthy African-American Adult Subjects

Role: lead

NCT01119833Phase 2Completed

Study of GMI-1070 for the Treatment of Sickle Cell Pain Crisis

Role: lead

NCT00911495Phase 1Completed

Study of Intravenous GMI-1070 in Adults With Sickle Cell Disease

Role: lead

NCT02811822Phase 1Completed

A Study to Determine the Efficacy, Safety and Pharmacokinetics of GMI-1271 as Adjunct to Standard of Care for the Treatment of Multiple Myeloma

Role: lead

NCT02744833Phase 1Terminated

Study to Assess Safety, Tolerability, and Efficacy of GMI-1271 in Patients With Calf-level Deep Venous Thrombosis (DVT)

Role: lead

NCT02306291Phase 1Completed

Study to Determine Safety, Pharmacokinetics and Efficacy of GMI-1271 in Combination With Chemotherapy in AML

Role: lead

NCT03606447Phase 1Completed

A Study in Healthy Volunteers to Investigate How Much Test Medicine [14C]-Uproleselan is Taken up by the Body When Administered Directly Into the Vein (IV)

Role: lead

NCT02931214Phase 1Completed

Placebo-Controlled Single Dose Study to Evaluate Safety and Pharmacokinetics of GMI-1359 in Healthy Volunteers

Role: lead